taking glp 1 for weight loss Most Patients Keep Off With Fewer GLP-1 Shots, Study Finds GLP-1 marketing evolves beyond easy

Twenty-four hours after scopolamine administration, the mice were reintroduced to the light compartment, and their step-through latencies to the dark compartment were measured

With global adoption of GLP-1s projected to surpass 100 million people by 2030, the average person using a GLP-1 medication still juggles several apps to track dosing, side effects, weight, and biometrics

Long-acting agents such as semaglutide should generally be discontinued at least two months before attempting conception

doi: 10.1007/s00253-020-10832-4 214 AzadMAKSarkerMWanD

J Diabetes Complications 37(8):108529 Mahapatra MK, Karuppasamy M, Sahoo BM (2022) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes